Carmen Lefaucheur received her qualification as Nephrologist in 2004 from Paris Descartes University. She defended her PhD in Biology and Biotechnology in 2012.
She obtained the “International Transplant Society New Key Opinion Leader Award” in 2010 and the “Prix de la Chancellerie des Universités de Paris” award in 2014.
Her research aims to develop a translational research model in organ transplantation based on a multidisciplinary approach which may connect immunological, histological, molecular and clinical knowledge. She has focused on the clinical relevance of HLA antibodies and their different mechanistic pathways leading to allograft antibody-mediated rejection, thereby addressing the heterogeneity of its phenotypic expression and eventually investigating new tailored potential therapies in transplant populations.
She is principal investigator of national and international clinical trials dedicated to prophylaxis and treatment of rejection in kidney transplantation. She is actually principal investigator in KTD-Innov and EU-train clinical studies whose goal is to develop and validate innovative tools for early prediction of individual risk prediction for allograft rejection and transplant loss.
Carmen Lefaucheur is involved in the French Speaking Society of Transplantation, in the Banff Conference Scientific Committee and in the Transplantation Society steering committee for guidelines on the treatment of antibody-mediated rejection.